The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis
<h4>Background</h4> Endometrial carcinoma (EC) is classified into four distinct molecular subgroups. Patients with polymerase epsilon exonuclease domain mutated (POLE-EDM) tumors have the best prognosis of all. This meta-analysis consolidated the clinicopathology variations reported in t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827442/?tool=EBI |
| _version_ | 1828193369702006784 |
|---|---|
| author | Alaa Salah Jumaah Hawraa Sahib Al-Haddad Katherine Ann McAllister Akeel Abed Yasseen |
| author_facet | Alaa Salah Jumaah Hawraa Sahib Al-Haddad Katherine Ann McAllister Akeel Abed Yasseen |
| author_sort | Alaa Salah Jumaah |
| collection | DOAJ |
| description | <h4>Background</h4> Endometrial carcinoma (EC) is classified into four distinct molecular subgroups. Patients with polymerase epsilon exonuclease domain mutated (POLE-EDM) tumors have the best prognosis of all. This meta-analysis consolidated the clinicopathology variations reported in the POLE-mutant subtype and survival parameters in patients with EC. <h4>Methods</h4> The following internet data bases were searched: PubMed, Web of science, Embase and Scimage directory. Data was extracted from eligible studies including sample size, number of positive POLE-mutant cases, EDM sequencing information, clinicopathologic, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odds ratios (OR). <h4>Results</h4> The meta-analysis included 11 cohort studies comprising 5508 EC patients (442 POLE EDM tumors). Patients with POLE mutant EC were associated with improved disease specific survival (HR = 0.408, 95% CI: 0.306 to 0.543) and progression-free survival (HR = 0.231, 95% CI: 0.117 to 0.456). POLE-mutated tumors were mostly endometrioid histology (84.480%; 95% CI: 77.237 to 90.548), although not significantly more than wild type tumors (OR = 1.386; p = 0.073). The POLE mutant tumors significantly present (p<0.001) at Federation of International of Gynecologists and Obstetricians (FIGO) lower stages I-II (OR = 2.955, p<0.001) and highest grade III (OR = 1.717, P = 0.003). The tumors are significantly associated with invasion less than half (<50%) of the myometrium (OR = 1.765, p = 0.001), but not deeply invasive EC (MI>50%, OR = 0.83, p = 0.34). POLE mutations significantly protected against lymph node metastases (OR = 0.202, p = 0.001), and have no clear association with lymph-vascular space invasion (OR = 0.967, 95% 0.713–1.310, p = 0.826). The tumors are predominantly of low ESMO risk stratification distribution (40.356%; 95% CI: 27.577 to 53.838). <h4>Conclusions</h4> POLE mutations serve as an important biomarker of favorable prognosis in EC. The tumors are characteristically high grade, early stage, and remain localized in the endometrium with reduced likelihood of lymph node metastasis for improved survival prospects and the lowest risk classification. These findings have implications for medical management of EC. |
| first_indexed | 2024-04-12T09:07:36Z |
| format | Article |
| id | doaj.art-ce3bcaeaace24f38897e5c4ae3757119 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T09:07:36Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ce3bcaeaace24f38897e5c4ae37571192022-12-22T03:39:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysisAlaa Salah JumaahHawraa Sahib Al-HaddadKatherine Ann McAllisterAkeel Abed Yasseen<h4>Background</h4> Endometrial carcinoma (EC) is classified into four distinct molecular subgroups. Patients with polymerase epsilon exonuclease domain mutated (POLE-EDM) tumors have the best prognosis of all. This meta-analysis consolidated the clinicopathology variations reported in the POLE-mutant subtype and survival parameters in patients with EC. <h4>Methods</h4> The following internet data bases were searched: PubMed, Web of science, Embase and Scimage directory. Data was extracted from eligible studies including sample size, number of positive POLE-mutant cases, EDM sequencing information, clinicopathologic, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odds ratios (OR). <h4>Results</h4> The meta-analysis included 11 cohort studies comprising 5508 EC patients (442 POLE EDM tumors). Patients with POLE mutant EC were associated with improved disease specific survival (HR = 0.408, 95% CI: 0.306 to 0.543) and progression-free survival (HR = 0.231, 95% CI: 0.117 to 0.456). POLE-mutated tumors were mostly endometrioid histology (84.480%; 95% CI: 77.237 to 90.548), although not significantly more than wild type tumors (OR = 1.386; p = 0.073). The POLE mutant tumors significantly present (p<0.001) at Federation of International of Gynecologists and Obstetricians (FIGO) lower stages I-II (OR = 2.955, p<0.001) and highest grade III (OR = 1.717, P = 0.003). The tumors are significantly associated with invasion less than half (<50%) of the myometrium (OR = 1.765, p = 0.001), but not deeply invasive EC (MI>50%, OR = 0.83, p = 0.34). POLE mutations significantly protected against lymph node metastases (OR = 0.202, p = 0.001), and have no clear association with lymph-vascular space invasion (OR = 0.967, 95% 0.713–1.310, p = 0.826). The tumors are predominantly of low ESMO risk stratification distribution (40.356%; 95% CI: 27.577 to 53.838). <h4>Conclusions</h4> POLE mutations serve as an important biomarker of favorable prognosis in EC. The tumors are characteristically high grade, early stage, and remain localized in the endometrium with reduced likelihood of lymph node metastasis for improved survival prospects and the lowest risk classification. These findings have implications for medical management of EC.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827442/?tool=EBI |
| spellingShingle | Alaa Salah Jumaah Hawraa Sahib Al-Haddad Katherine Ann McAllister Akeel Abed Yasseen The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis PLoS ONE |
| title | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis |
| title_full | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis |
| title_fullStr | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis |
| title_full_unstemmed | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis |
| title_short | The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis |
| title_sort | clinicopathology and survival characteristics of patients with pole proofreading mutations in endometrial carcinoma a systematic review and meta analysis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827442/?tool=EBI |
| work_keys_str_mv | AT alaasalahjumaah theclinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT hawraasahibalhaddad theclinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT katherineannmcallister theclinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT akeelabedyasseen theclinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT alaasalahjumaah clinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT hawraasahibalhaddad clinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT katherineannmcallister clinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis AT akeelabedyasseen clinicopathologyandsurvivalcharacteristicsofpatientswithpoleproofreadingmutationsinendometrialcarcinomaasystematicreviewandmetaanalysis |